Detailed explanation of the differences in efficacy and indications between inalisate (Iheli) and carpisetin

Inalisate is an oral and selective PI3Kα inhibitor that mainly targets the PIK3CA gene mutation-related signaling pathways to inhibit tumor cell proliferation and survival. Its target is highly selective and is mainly used for patients with PIK3CA mutation-positive breast cancer. In contrast, carpizote is a AKTkinase inhibitor, acting downstream of the PI3K/AKT/mTOR pathway The AKT target can block tumor cell growth and anti-apoptotic signals. It has a wider target coverage and is suitable for tumors activated by a variety of PI3K/AKT/mTOR pathways.

Inalise is mainly used for patients with HR+/HER2- advanced or metastatic breast cancer PIK3CA mutations. Combined with endocrine therapy, it can prolong progression-free survival. Carpisetin has a wide range of indications. In addition to HR+/HER2- breast cancer, it is also undergoing clinical research in ovarian cancer, prostate cancer and other tumors with abnormal PI3K/AKT/mTOR pathways. Its use does not entirely depend on PIK3CA mutation status.

Inaliset has significant efficacy in mutation-positive patients. The main side effects are hyperglycemia, rash, diarrhea and mild liver function abnormalities, and it is well tolerated. Carpiseti has shown efficacy in a variety of tumor types, but the side effects cover a wider range, including hyperglycemia, diarrhea, rash, fatigue and hyponatremia, requiring stricter monitoring of blood sugar and electrolytes.

Clinically, for breast cancer patients with confirmed PIK3CA mutations, inaliset can be used as the first-choice targeted drug; while for patients with extensive or unknown pathway activation status, carpisetin has wider applicability. Drug selection needs to be based on gene mutation status, tumor type, previous treatment history and patient tolerance, and an individualized plan should be developed under the guidance of professional doctors to achieve maximum efficacy and safety.

Reference link:https://www.drugs.com